Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07270432

Efficacy/ Safety of Product DNN.65.21.005 in Patients With Benign Prostatic Hyperplasia

Randomized Clinical Trial to Evaluate the Safety and Efficacy of Product DNN.65.21.005 in Alleviating Lower Urinary Tract Symptoms in Patients With Benign Prostatic Hyperplasia

Status
Not Yet Recruiting
Phase
Phase 3
Study type
Interventional
Enrollment
218 (estimated)
Sponsor
Ache Laboratorios Farmaceuticos S.A. · Industry
Sex
Male
Age
50 Years
Healthy volunteers
Not accepted

Summary

To evaluate the safety and efficacy of DNN.65.21.005 versus Combodart® in the treatment of benign prostatic hyperplasia

Conditions

Interventions

TypeNameDescription
DRUGProduct DNN.65.21.005One capsule every 24 hours
DRUGCombodart®One capsule every 24 hours

Timeline

Start date
2026-01-01
Primary completion
2027-04-01
Completion
2027-04-01
First posted
2025-12-08
Last updated
2025-12-08

Source: ClinicalTrials.gov record NCT07270432. Inclusion in this directory is not an endorsement.